Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis

Janus kinase (JAK) inhibitors, a novel class of targeted synthetic disease-modifying antirheumatic drugs (DMARDs), have shown their safety and efficacy in rheumatoid arthritis (RA) and are being intensively tested in other autoimmune and inflammatory disorders. Targeting several cytokines with a sin...

Descripción completa

Detalles Bibliográficos
Autores principales: Kotyla, Przemysław J., Islam, Md Asiful, Engelmann, Małgorzata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583966/
https://www.ncbi.nlm.nih.gov/pubmed/33036382
http://dx.doi.org/10.3390/ijms21197390

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583966/
https://www.ncbi.nlm.nih.gov/pubmed/33036382
http://dx.doi.org/10.3390/ijms21197390

Ejemplares similares